01929nam 22004331 450 991067847180332120180103162434.31-5264-3112-2(CKB)4100000001482268(OCoLC)1023546327(CaToSAGE)SAGE000003238(EXLCZ)99410000000148226820180103e20172017 fy| 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierAmgen launching Repatha /Tim Calkins, Mike HarrisLondon :Kellogg School of Management,2017.1 online resource illustrationsSAGE Knowledge. CasesOriginally published in Calkins, T., & Harris, M. (2017). Amgen: Launching Repatha. 5-416-759. Evanston, IL: Kellogg School of Management at Northwestern University.In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven that the molecule is both safe and effective for patients with high cholesterol. It also is effective for patients with familial hypercholesterolemia, a difficult-to-treat population that has exceptionally high levels of cholesterol. Amgen expects the FDA to approve the molecule before the end of the year. Now, the Repatha team has to develop a revenue forecast.SAGE Knowledge.Cases.HeartDiseasesTreatmentUnited StatesHypercholesteremiaHeartDiseasesTreatmentHypercholesteremia.616.12Calkins Tim507376Harris MikeCaToSAGECaToSAGEUtOrBLWBOOK9910678471803321Amgen3073104UNINA